David W. Osborne, Chief Technical Officer at Arcutis Biotherapeutics, Inc. (ARQT), sold 2,197 shares at $20.42 ($45K) on 2022-04-21, disclosed to the SEC on 2022-04-21.
Scheduled sale ($45k) by Chief Technical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ARQT | SELL | 2022-07-12 | $112K | — | Filing → |
| ARQT | SELL | 2022-03-07 | $14K | — | Filing → |
| ARQT | SELL | 2022-03-03 | $14K | — | Filing → |